文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用于战斗的活体药物:嵌合抗原受体T细胞疗法综述

Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.

作者信息

Vinoo Saasha, Jaiswal Divya, Mehta Palak, Battu Atharv, Majumdar Anuradha

机构信息

Department of Pharmacology, Bombay College of Pharmacy, Kalina, Santa Cruz (E), Mumbai, 400098, India.

出版信息

Int J Hematol Oncol Stem Cell Res. 2025 Apr 1;19(2):180-190. doi: 10.18502/ijhoscr.v19i2.18555.


DOI:10.18502/ijhoscr.v19i2.18555
PMID:40852701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12368713/
Abstract

The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.

摘要

癌症治疗方面的大量进展促使人们设计出独特的特征标识和个性化疗法,根据患者的特定需求,使用针对癌细胞特定标志物的药物,甚至重新训练人体免疫系统。嵌合抗原受体T细胞(也称为CAR T细胞)就是这样一种方法,即对患者的细胞进行调节以杀死癌细胞。传统的癌症治疗会引发一些问题,比如特异性低、复发几率增加,或者在化疗情况下存在放射毒性和耐受性问题。目前,CAR T细胞疗法正在进行临床研究,不同国家仍在制定CAR T实际应用的指南。在这篇综述中,我们介绍了关于CAR T细胞疗法人们需要了解的一切,包括其类型、组成部分、副作用、在不同国家的当前获批情况,以及该疗法所使用的技术。我们还简要提及了欧洲和美国这两个积极推动CAR T理念的国家最近发布的法规或指南。这篇综述旨在深入了解这种靶向疗法,它有可能推动癌症研究,并帮助研究人员开发更多此类针对患者的治疗方法,以改善癌症的临床治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b92/12368713/88e0509c2b6f/IJHOSCR-19-180-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b92/12368713/85132abf6540/IJHOSCR-19-180-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b92/12368713/88e0509c2b6f/IJHOSCR-19-180-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b92/12368713/85132abf6540/IJHOSCR-19-180-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b92/12368713/88e0509c2b6f/IJHOSCR-19-180-g002.jpg

相似文献

[1]
Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.

Int J Hematol Oncol Stem Cell Res. 2025-4-1

[2]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[3]
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Cochrane Database Syst Rev. 2021-9-13

[4]
B cell antigens: A key to optimizing CAR-T cell therapy.

Int Rev Immunol. 2025-6-19

[5]
In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.

PLoS Comput Biol. 2022-3

[6]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[7]
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.

Int J Mol Sci. 2024-6-29

[8]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[9]
Immunotherapy in Glioblastoma: An Overview of Current Status.

Clin Pharmacol. 2025-7-24

[10]
Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs).

Health Technol Assess. 2025-8

本文引用的文献

[1]
Advanced therapy medicinal products in China: Regulation and development.

MedComm (2020). 2023-4-26

[2]
Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.

Cancer Med. 2023-4

[3]
Automated, scaled, transposon-based production of CAR T cells.

J Immunother Cancer. 2022-9

[4]
Toward Rapid, Widely Available Autologous CAR-T Cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital.

Front Med (Lausanne). 2022-6-6

[5]
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.

Hematol Oncol. 2022-10

[6]
Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR-T.

Clin Case Rep. 2022-4-8

[7]
The potential of CAR T cell therapy for prostate cancer.

Nat Rev Urol. 2021-9

[8]
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.

Int J Mol Sci. 2021-5-24

[9]
CAR-T cell therapy: current limitations and potential strategies.

Blood Cancer J. 2021-4-6

[10]
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.

Expert Opin Biol Ther. 2021-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索